|Bid||86.48 x 200|
|Ask||86.50 x 300|
|Day's Range||86.44 - 87.29|
|52 Week Range||69.53 - 87.29|
|PE Ratio (TTM)||30.87|
|Forward Dividend & Yield||2.72 (3.14%)|
|1y Target Est||N/A|
Should Investors Be Interested in Vertex Pharmaceuticals in 2018? On October 25, 2017, Vertex Pharmaceuticals (VRTX) announced positive top-line results from its open-label Phase 3 trial that evaluated Orkambi in 60 children suffering with cystic fibrosis (or CF) who have two copies of the F508del mutation. The trial reached its primary endpoint of safety, and Orkambi demonstrated improvement in secondary endpoints such as nutritional status and sweat chloride.
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? The Vanguard Total International Stock ETF (VXUS) holds 0.09% of its total portfolio in TEVA stock. Teva Pharmaceutical Industries (TEVA) has its biggest value chain in the market as the company’s core strength, which has helped it establish itself as the leading generics pharmaceutical company in the world.
Novartis has been granted fast-track reviews of its cell therapy Kymriah for blood cancers in the United States and Europe, the Swiss drugmaker said on Wednesday, as it seeks to expand the pool of patients eligible for the costly treatment. Kymriah, already approved for treatment of children and young adults with r/r B-cell acute lymphoblastic leukemia (ALL), will now get speedy scrutiny by the U.S. Food and Drug Administration for use against relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) in adults, the company said in a statement. In addition, the European Medicines Agency granted an accelerated assessment for Kymriah in children and young adults with ALL.
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? As we saw in the previous part of this series, Teva Pharmaceutical Industries (TEVA) is determined to pay down a considerable amount of its debt totaling $32 billion over the next few years. The company aims to achieve financial stability through improvement in operating profits and stable cash flow generation over the next few years.
Novartis (NVS) Biologics License Application (BLA) for the proposed biosimilar of blockbuster drug Humira was accepted by the FDA under the 351 (k) pathway.
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? In December 2017, Teva Pharmaceutical Industries (TEVA) announced a restructuring plan to recuperate sales. Its stock has had a bull run since the announcement, rising 44.5% since the company’s weak earnings results for fiscal 3Q17 on November 2, 2017.
On the heels of collaborations with Bristol-Myers Squibb (BMY) and Allergan (AGN), Chapel Hill-based clinical data company Target PharmaSolutions’ latest collaboration is with Novartis (NVS). Novartis will collaborate with Target on its NASH study, focused on patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).
Novartis (NVS) announced the initiation of a trial on the biosimilar version of Cosentyx which will compare the drug to its proposed biosimilar for the treatment of ankylosing spondylitis.
In 3Q17, Imbruvica reported global revenues close to $688 million for AbbVie (ABBV). This represented a YoY (year-over-year) growth of ~37.3%. The drug reported revenues of close to $574 million in the US, which represents a YoY rise a close to 31.0%.
The agreement granted Ignyta exclusive global rights to develop and commercialize entrectinib. Under the license, Ignyta’s development rights are exclusive for entrectinib for the term of the agreement. The license also grants exclusive rights to Ignyta for a term of five years with respect to any product candidate that NMS might develop that has activity against the target proteins of entrectinib.
AbbVie (ABBV) has projected Imbruvica’s annual revenues to reach $5 billion by 2020. The drug has already changed the treatment paradigm in the second line plus CLL segment and for CLL patients with 17p deletion. AbbVie expects that in the future, nearly eight out of ten CLL patients will benefit from an Imbruvica-based therapy at one point or another.
Delaware-based Ignyta (RXDX) is focused on precision medicine in oncology. It endeavors to eradicate residual disease or the source of a reoccurrence of cancer in targeted patient populations. Ignyta is pursuing an integrated therapeutic and diagnostic strategy to treat cancer patients.
As we discussed earlier, Incyte (INCY) reported revenue of $381.5 million in 3Q17, a 41.6% rise over its revenue of $269.5 million in 3Q16. This revenue growth was driven by increased demand for the drug Jakafi. The above graph shows a revenue breakup for Incyte over the last few quarters.